Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 4 of 4

Publication Record

Connections

Isotope-Labeling Studies Support the Electrophilic Compound I Iron Active Species, FeO(3+), for the Carbon-Carbon Bond Cleavage Reaction of the Cholesterol Side-Chain Cleavage Enzyme, Cytochrome P450 11A1.
Yoshimoto FK, Jung IJ, Goyal S, Gonzalez E, Guengerich FP
(2016) J Am Chem Soc 138: 12124-41
MeSH Terms: Alcohol Dehydrogenase, Caproates, Carbon, Cholesterol, Cholesterol Side-Chain Cleavage Enzyme, Ferric Compounds, Isotope Labeling, Oxygen, Yeasts
Show Abstract · Added March 14, 2018
The enzyme cytochrome P450 11A1 cleaves the C20-C22 carbon-carbon bond of cholesterol to form pregnenolone, the first 21-carbon precursor of all steroid hormones. Various reaction mechanisms are possible for the carbon-carbon bond cleavage step of P450 11A1, and most current proposals involve the oxoferryl active species, Compound I (FeO(3+)). Compound I can either (i) abstract an O-H hydrogen atom or (ii) be attacked by a nucleophilic hydroxy group of its substrate, 20R,22R-dihydroxycholesterol. The mechanism of this carbon-carbon bond cleavage step was tested using (18)O-labeled molecular oxygen and purified P450 11A1. P450 11A1 was incubated with 20R,22R-dihydroxycholesterol in the presence of molecular oxygen ((18)O2), and coupled assays were used to trap the labile (18)O atoms in the enzymatic products (i.e., isocaproaldehyde and pregnenolone). The resulting products were derivatized and the (18)O content was analyzed by high-resolution mass spectrometry. P450 11A1 showed no incorporation of an (18)O atom into either of its carbon-carbon bond cleavage products, pregnenolone and isocaproaldehyde . The positive control experiments established retention of the carbonyl oxygens in the enzymatic products during the trapping and derivatization processes. These results reveal a mechanism involving an electrophilic Compound I species that reacts with nucleophilic hydroxy groups in the 20R,22R-dihydroxycholesterol intermediate of the P450 11A1 reaction to produce the key steroid pregnenolone.
0 Communities
1 Members
0 Resources
9 MeSH Terms
The effect of aprotinin on outcome after coronary-artery bypass grafting.
Shaw AD, Stafford-Smith M, White WD, Phillips-Bute B, Swaminathan M, Milano C, Welsby IJ, Aronson S, Mathew JP, Peterson ED, Newman MF
(2008) N Engl J Med 358: 784-93
MeSH Terms: Aged, Aminocaproates, Antifibrinolytic Agents, Aprotinin, Blood Loss, Surgical, Cohort Studies, Coronary Artery Bypass, Coronary Disease, Creatinine, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Kidney, Kidney Diseases, Logistic Models, Middle Aged, Mortality, Renal Dialysis, Retrospective Studies, Treatment Outcome
Show Abstract · Added October 20, 2015
BACKGROUND - Aprotinin has recently been associated with adverse outcomes in patients undergoing cardiac surgery. We reviewed our experience with this agent in patients undergoing cardiac surgery at Duke University Medical Center.
METHODS - We retrieved data on 10,275 consecutive patients undergoing surgical coronary revascularization at Duke between January 1, 1996, and December 31, 2005. We fit data to a logistic-regression model predicting each patient's likelihood of receiving aprotinin on the basis of preoperative characteristics and to models predicting long-term survival (up to 10 years) and decline in renal function, as measured by increases in serum creatinine levels.
RESULTS - A total of 1343 patients (13.2%) received aprotinin, 6776 patients (66.8%) received aminocaproic acid, and 2029 patients (20.0%) received no antifibrinolytic therapy. All patients underwent coronary-artery bypass grafting, and 1181 patients (11.5%) underwent combined coronary-artery bypass grafting and valve surgery. In the risk-adjusted model, survival was worse among patients treated with aprotinin, with a main-effects hazard ratio for death of 1.32 (95% confidence interval [CI], 1.12 to 1.55) for the comparison with patients receiving no antifibrinolytic therapy (P=0.003) and 1.27 (95% CI, 1.10 to 1.46) for the comparison with patients receiving aminocaproic acid (P=0.004). As compared with the use of aminocaproic acid or no antifibrinolytic agent, aprotinin use was also associated with a larger risk-adjusted increase in the serum creatinine level (P<0.001) but not with a greater risk-adjusted incidence of dialysis (P=0.56).
CONCLUSIONS - Patients who received aprotinin had a higher mortality rate and larger increases in serum creatinine levels than those who received aminocaproic acid or no antifibrinolytic agent.
Copyright 2008 Massachusetts Medical Society.
0 Communities
1 Members
0 Resources
20 MeSH Terms
Exercise improves albumin fractional synthetic rate in chronic hemodialysis patients.
Pupim LB, Flakoll PJ, Ikizler TA
(2007) Eur J Clin Nutr 61: 686-9
MeSH Terms: Albumins, Caproates, Carbon Isotopes, Cross-Over Studies, Exercise, Female, Humans, Kidney Failure, Chronic, Leucine, Male, Middle Aged, Parenteral Nutrition, Renal Dialysis, Serum Albumin
Show Abstract · Added September 29, 2014
OBJECTIVE - To determine whether exercise augments the improvements in fractional synthetic rate (FSR) of albumin observed with nutrition alone.
DESIGN - Randomized crossover study. Each patient randomly participated in two protein metabolism kinetic studies using primed-constant infusion of (13C) leucine 2 h before, during and 2 h after hemodialysis. Plasma enrichments of (13C) leucine and (13C) ketoisocaproate were examined to determine the FSR of albumin.
SETTING - General Clinical Research Center at Vanderbilt University Medical Center.
SUBJECTS - Five chronic hemodialysis (CHD) patients.
INTERVENTIONS - Intra-dialytic parenteral nutrition (IDPN) with or without exercise.
RESULTS - Exercise performance during hemodialysis significantly improves the FSR of albumin beyond what is observed with IDPN alone (26.2+/-3.1% per day versus 17.7+/-1.9% per day, P<0.05).
CONCLUSION - Exercise improves albumin fractional synthetic rate beyond what is observed with IDPN alone in the acute setting in CHD patients.
0 Communities
1 Members
0 Resources
14 MeSH Terms
Role of prothrombin fragment 1 in the pathway of regulatory exosite I formation during conversion of human prothrombin to thrombin.
Anderson PJ, Bock PE
(2003) J Biol Chem 278: 44489-95
MeSH Terms: 4-Chloro-7-nitrobenzofurazan, Aminocaproates, Binding Sites, Enzyme Precursors, Factor Va, Fluoresceins, Fluorescent Dyes, Hirudins, Humans, Peptide Fragments, Protein Precursors, Prothrombin, Spectrometry, Fluorescence, Thrombin
Show Abstract · Added January 20, 2015
Prothrombin (Pro) activation by factor Xa generates the thrombin catalytic site and exosites I and II. The role of fragment 1 (F1) in the pathway of exosite I expression during Pro activation was characterized in equilibrium binding studies using hirudin(54-65) labeled with 6-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoate ([NBD]Hir(54-65)(SO3-)) or 5-(carboxy)fluorescein ([5F]Hir(54-65)(SO3-)). [NBD]Hir(54-65)(SO3-) distinguished exosite I environments on Pro, prethrombin 1 (Pre 1), and prethrombin 2 (Pre 2) but bound with the same affinities as [5F]Hir(54-65)(SO3-). Conversion of Pro to Pre 1 caused a 7-fold increase in affinity for the peptides. Conversely, fragment 1.2 (F1.2) decreased the affinity of Pre 2 for [5F]Hir(54-65)(SO3-) by 3-fold. This was correlated with a 16-fold increased affinity of F1.2 for Pre 2 in comparison to thrombin, demonstrating an enhancing effect of F1 on F1.2 binding. The active intermediate, meizothrombin, demonstrated a 50- to 220-fold increase in exosite affinity. Free thrombin and thrombin.F1.2 complex bound [5F]Hir(54-65)(SO3-) with indistinguishable affinity, indicating that the effect of F1 on peptide binding was eliminated upon expression of catalytic activity and exosite I. The results demonstrate a new zymogen-specific role for F1 in modulating the affinity of ligands for exosite I. This may reflect a direct interaction between the F1 and Pre 2 domains in Pro that is lost upon folding of the zymogen activation domain. The effect of F1 on (pro)exosite I and the role of (pro)exosite I in factor Va-dependent substrate recognition suggest that the Pro activation pathway may be regulated by (pro)exosite I interactions with factor Va.
0 Communities
1 Members
0 Resources
14 MeSH Terms